ACT-179811 in Patients With Clostridium Difficile Infection
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/18/2012 |
| Start Date: | December 2010 |
| End Date: | October 2012 |
Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety & Tolerability of 3 Doses of ACT-179811 in Subjects With Clostridium Difficile Infection
Subjects with Clostridium Difficile Infection (CDI) are randomized and then treated with
study drug for 10 days.
At the end of treatment, cure is assessed; subjects are then followed-up to assess any
disease recurrence.
Inclusion Criteria:
- male or female
- at least 18 year old
- CDI 1st occurrence or 1st recurrence
Exclusion Criteria:
- concurrent life threatening condition
- concomitant antimicrobial treatment for CDI
- concomitant treatment with another investigational drug.
We found this trial at
11
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials